BCTX: Second Quarter Results
By John Vandermosten, CFA
NASDAQ:BCTX
READ THE FULL BCTX RESEARCH REPORT
OPNT: Data from OPNT003 Pharmacodynamic Trial in 2Q22…
By David Bautz, PhD
NASDAQ:OPNT
READ THE FULL OPNT RESEARCH REPORT
Emergent BioSolutions: Q4 Earnings Insights
Emergent BioSolutions (NYSE:EBS) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.
Johnson & Johnson’s COVID-19 Shot Wins Its First Full Approval In Canada
Canada has become the first country to fully approve Johnson & Jo
Benchmark Downgrades Emergent BioSolutions to Hold
Benchmark analyst Robert Wasserman downgrades Emergent BioSolutions (NYSE:EBS) from Buy to Hold.
See Why Emergent BioSolutions Stock Plunged 37% On Friday?
After a fiasco surrounding the contamination of COVID-19 vaccine doses in its facilities, Emergent BioSolutions Inc's (NYSE: EBS) manufacturing deal with the US government has come to an end.
Mid-Afternoon Market Update: Dow Surges 200 Points; Grid Dynamics Shares Spike Higher
Toward the end of trading Friday, the Dow traded up 0.57% to 36,331.86 while the NASDAQ rose 0.20% to 15,972.41. The S&P also rose, gaining 0.40% to 4,698.70.